We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with anti‐IL‐5/IL‐5R biologics.
- Authors
Lorente‐Sorolla, C.; Bernaola, J.; Sánchez‐Mellado, D.; Gil‐Martínez, M.; Naharro‐González, S.; Betancor, D.; Fernández‐Nieto, M.; Pinillos‐Robles, E. J.; Santillán Coello, J. M.; Villacampa‐Aubá, J. M.; Rodríguez‐Nieto, M. J.; Sastre, J.; Valverde‐Monge, M.; Rodrigo‐Muñoz, J. M.; del Pozo, V.
- Abstract
This article presents a study comparing the clinical and immunological outcomes of two biological treatments, benralizumab and mepolizumab, for severe eosinophilic asthma. The study found that both treatments improved lung function, reduced exacerbations, and enhanced quality of life measures. However, benralizumab had a greater effect on certain cytokines and mediators compared to mepolizumab. The authors suggest that these findings could potentially be used as biomarkers for treatment selection, but more research is needed to confirm these results in lung tissue.
- Subjects
TREATMENT effectiveness; IMMUNE response; ASTHMATICS; BIOLOGICALS; LUNGS
- Publication
Allergy, 2023, Vol 78, Issue 11, p3027
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15872